VANCOUVER, June 12, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (the "Company") announces that Mr.
Jason Tian will be joining its Board
of Directors. Jason Tian is a Senior
Partner at Landing Law offices based in Shanghai, China. Jason has been working with
Sirona since 2018 representing the Company at strategic partnering
meetings in China and France.
Jason Tian has been providing
legal services to international clients since 2007 and has worked
in top firms in China such as
Beijing Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a
Senior Partner of Shanghai Landing Law Offices. He also worked as
senior legal translator in UK-based firm, Clifford Chance LLP,
before starting his legal career.
Shanghai Landing Law Offices is a full-service law firm with
headquarters in Shanghai,
China. Lawyers at Landing provide full-service to clients in
industries such as healthcare and pharmaceuticals as well as
consumer retail in China. Landing
has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia, Bangladesh, Philippines and Cambodia.
"Sirona's management team has developed an excellent working
relationship with Jason. His legal knowledge and extensive network
in the Chinese business community are proving to be tremendous
assets to Sirona", reports Sirona Biochem's CEO Dr Howard Verrico.
The company also announces Casper
Bych has resigned from Sirona's Board of Directors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
---------------------------------------------
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law. The
appointment of Jason Tian to the BOD
is subject to exchange approval.
SOURCE Sirona Biochem Corp.